JP2024514163A5 - - Google Patents

Info

Publication number
JP2024514163A5
JP2024514163A5 JP2023562872A JP2023562872A JP2024514163A5 JP 2024514163 A5 JP2024514163 A5 JP 2024514163A5 JP 2023562872 A JP2023562872 A JP 2023562872A JP 2023562872 A JP2023562872 A JP 2023562872A JP 2024514163 A5 JP2024514163 A5 JP 2024514163A5
Authority
JP
Japan
Prior art keywords
days
hours
therapeutic agent
subject
cell preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025115 external-priority patent/WO2022221726A2/en
Publication of JP2024514163A publication Critical patent/JP2024514163A/ja
Publication of JP2024514163A5 publication Critical patent/JP2024514163A5/ja
Pending legal-status Critical Current

Links

JP2023562872A 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法 Pending JP2024514163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176196P 2021-04-16 2021-04-16
US63/176,196 2021-04-16
PCT/US2022/025115 WO2022221726A2 (en) 2021-04-16 2022-04-15 Combination therapies with bcma-directed t cell therapy

Publications (2)

Publication Number Publication Date
JP2024514163A JP2024514163A (ja) 2024-03-28
JP2024514163A5 true JP2024514163A5 (https=) 2025-04-18

Family

ID=81846411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562872A Pending JP2024514163A (ja) 2021-04-16 2022-04-15 Bcma指向性t細胞療法を用いた併用療法

Country Status (9)

Country Link
US (1) US20240207310A1 (https=)
EP (1) EP4322959A2 (https=)
JP (1) JP2024514163A (https=)
KR (1) KR20230171468A (https=)
CN (1) CN118201618A (https=)
AU (1) AU2022258832A1 (https=)
CA (1) CA3214683A1 (https=)
IL (1) IL307612A (https=)
WO (1) WO2022221726A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
PL3198345T3 (pl) 2014-09-22 2021-08-23 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linia do produkcji pojedynczych wyrobów w następujących po sobie w cyklu ciągłym
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
CN106014789A (zh) 2016-06-25 2016-10-12 郭远军 一种悬吊式一体化反装斜击式水轮发电机及其做功方法
US20200371091A1 (en) * 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
TW202019474A (zh) * 2018-07-11 2020-06-01 美商西建公司 抗bcma嵌合抗原受體之用途
CA3117978A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
US20230165872A1 (en) * 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound

Similar Documents

Publication Publication Date Title
JP7526121B2 (ja) キメラ抗原受容体を使用する癌の処置
JP2024167225A (ja) キメラ抗原受容体とpd-1阻害薬との併用療法
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
JP2020528750A (ja) 抗ctla−4抗体およびその使用
AU2017225733A1 (en) Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN115916199A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN113271945A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
CN115175935A (zh) Cal-t构建体及其用途
JP2023524430A5 (https=)
JP2025175307A (ja) 逐次抗cd19治療
CA3170020A1 (en) Anti-hpv t cell receptors and engineered cells
JP2024514163A5 (https=)
CN119095869A (zh) 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
JP2024513054A5 (https=)
KR20230007384A (ko) 치료 방법
JP2024540320A5 (https=)
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
TW202611075A (zh) 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法
IL297697A (en) Preparations and methods for improving chimeric antigen receptor t cell therapies
JP2026510808A (ja) ヒト抗体を標的とするメラノーマとその治療方法
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法